Pharmaceuticals
ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results
SEOUL, South Korea, March 11, 2024 /PRNewswire/ -- ImmunAbs, a leading clinical-stage biotechnology company focused on developing novel antibody therapeutics, today announced the successful completion of the Phase 1 clinical trial for IM-101. IM-101 is a humanized monoclonal antibody targeting...
2024-03-11 17:00
2710
AI Empowers Surgery: CAIR unveils its latest large multimodality model for surgery
HONG KONG, March 11, 2024 /PRNewswire/ -- As artificial intelligence technology continues to advance, it has accelerated intelligent innovation across various industries. Breakthroughs in AI technologies like GPT have gained widespread attention, especially in the healthcare sector, where they of...
2024-03-11 15:06
2168
Apollo Hospitals Unveils South Asia's First ZAP-X, Transforming Brain Tumor Care
NEW DELHI, March 11, 2024 /PRNewswire/ -- Apollo Hospitals becomes the first hospital to introduce ZAP-X Gyroscopic Radiosurgery Platform, a significant milestone as the first inSouth Asia to introduce this ground-breaking technology. ZAP-X introduces a new era in brain tumor treatment, offering ...
2024-03-11 15:00
2823
RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024
YANTAI, China, March 11, 2024 /PRNewswire/ -- RemeGen Co. Ltd.
2024-03-11 10:36
2531
Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau
-- Macau is on course to become the first of Everest's Asian territories to get etrasimod approval -- Can provide access to patients in China's Greater Bay area and rest of Asia SHANGHAI, March 11, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceu...
2024-03-11 09:00
4226
Launch of CMDF Showcase Event to Share Achievements, Promote Chinese Medicine Culture to Public and Remark a New Mileage of Chinese Medicine Development
HONG KONG, March 9, 2024 /PRNewswire/ -- In 2019, the HKSAR Government officially launched the Chinese Medicine Development Fund (CMDF) to promote the development and elevate the overall standards of the Chinese medicine (CM) sector inHong Kong. Starting from today, the CMDF will host a four-day ...
2024-03-09 18:17
3608
Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024
ROCKVILLIE, Md. and SUZHOU, China, March 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and...
2024-03-07 11:53
3951
Luye Pharma's Innovative Drug Zepzelca® (Lurbinectedin) Launched in Hong Kong and Macao
Reshaping the landscape for the second-line treatments of Small Cell Lung Cancer HONG KONG and MACAO, March 7, 2024 /PRNewswire/ -- A symposium called the New Treatment Paradigm for Small Cell Lung Cancer (SCLC) organized by the Hong Kong Cancer Therapy Society (HKCTS) with support from Luye Phar...
2024-03-07 10:11
4263
A Global Milestone in Innovative Pancreatic Cancer Therapy
Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy developed in-house by BioGate. TAIPEI, March 7, 2024 /PRNewswire/ -- BioGate Precision Medicine Corp., a memb...
2024-03-07 10:00
3062
Epitomee® announces the filing of a novel Weight Loss Capsule for FDA clearance
CAESAREA, Israel, March 7, 2024 /PRNewswire/ -- Epitomee® (TASE: EPIT) announced today that onFebruary 27, 2024, it has submitted its Weight Loss Capsule for FDA clearance in theUSA, reaching a significant milestone in the company's journey. The Epitomee® capsule offers an innovative, orally adm...
2024-03-07 09:00
2489
Latest Updates of Viva Biotech's Portfolio Companies
HONG KONG, March 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...
2024-03-06 19:33
3083
Innovative Visionary Mark W. Womack Strengthens Bridgewest Perth Pharma Pty Ltd Board, Amplifying NovaCina's Growth Vision
Mark W. Womack Named to Bridgewest Perth Pharma Pty Ltd Board of Directors MIAMI and PERTH, Australia, March 6, 2024 /PRNewswire/ -- Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, with subsidiaries NovaCina and LumaCina, announced today the appointment ofMark W...
2024-03-06 12:29
2772
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024
SHANGHAI, March 6, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will report financial results for the fu...
2024-03-06 08:59
3295
Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblastoma
The independent data monitoring committee (IDMC) has recommended continuation of CLINGLIO without modification after its assessment of LAM561 interim efficacy in newly diagnosed Glioblastoma. This follows the previous recommendation in relation to safety. CLINGLIO remains on track to have its op...
2024-03-06 08:45
2303
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms
* The first preclinical abstract on ATG-O42 (MTAPnull-selective small molecule PRMT5 inhibitor) as well as the latest data on the proprietary T cell engager platform, AnTenGagerTM, and ATG-102 (LILRB4 x CD3 T cell engager). * The first view of ATG-022 (Claudin 18.2 ADC) companion diagnostic. S...
2024-03-06 08:30
2936
Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024
* Presentations will highlight the broad potential treatment opportunities for its clinical-stage targeted therapeutics HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) with further demonstrations of their pre-clinical efficacy in additional indications and deeper studies of their underly...
2024-03-06 05:30
2586
IRBM Expands Global Reach in Drug Discovery with New Boston Office
Strategic Growth and Increased Visibility Set to Enhance IRBM's Leadership Position ROME, March 5, 2024 /PRNewswire/ -- IRBM, an integrated drug discovery Contract Research Organization (CRO), announces its global expansion with a new office inBoston, Massachusetts, a cornerstone for biotechnolo...
2024-03-05 20:24
2843
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2024-03-05 13:35
3528
First Patient Treated in Phase 2 GvHD Trial
MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial ofCYP-001...
2024-03-05 10:08
2606
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manuf...
2024-03-05 07:01
2510
Week's Top Stories
Most Reposted
Agoda Launches Free Global eSIMs for VIP Diamond Members
[Picked up by 322 media titles]
2026-02-10 14:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Blackpanda Japan Announces Strategic Partnership with SoftBank to Strengthen Cyber Incident Response in Japan
[Picked up by 298 media titles]
2026-02-10 13:31Rockwell Automation Strengthens Industrial Cybersecurity with New Security Operations Center in Singapore
[Picked up by 298 media titles]
2026-02-09 10:00
Carro unveils quirky generative AI ad campaign highlighting its 'Surprisingly Short' AI-enabled car-selling process
[Picked up by 296 media titles]
2026-02-11 11:00
Most Read
Rockwell Automation Strengthens Industrial Cybersecurity with New Security Operations Center in Singapore
2026-02-09 10:00
8061
AIA RESEARCH REVEALS INGRAINED HEALTH STEREOTYPES ARE HOLDING BACK WELLBEING IN ASIA
2026-02-09 16:08
6443
Aon and KNIAZHA VIENNA INSURANCE GROUP announce new $25M war-risk insurance facility with the U.S. International Development Finance Corporation
2026-02-09 22:42
6290
Agoda Launches Free Global eSIMs for VIP Diamond Members
2026-02-10 14:00
5800
